Home › Kanser sa Suso › Wisconsin › Madison
Pag-aaral pangklinika para sa Kanser sa Suso sa Madison, WI
Isang pag-aaral para sa Kanser sa Suso ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Madison. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Nagre-recruitPhase 3
- University of Wisconsin Carbone Cancer Center- University Hospital, Madison
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Nagre-recruitPhase 1/2
- University of Wisconsin Carbone Cancer Center, Madison
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Nagre-recruitPhase 2
- UW Health Carbone Cancer Center, Madison
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- William S Middleton VA Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Nagre-recruitPhase 2
- University of Wisconsin, Madison
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Nagre-recruitPhase 1
- Wisconsin Institute for Medical Research, Madison
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Nagre-recruitPhase 3
- Circuit Clinical/SSM Health Dean Medical Group ( Site 0039), Madison
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Nagre-recruitPhase 3
- University Hospital and UW Health Clinics-Carbone Cancer Center ( Site 0040), Madison
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Nagre-recruitPhase 3
- University of Wisconsin-Madison ( Site 0024), Madison
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Nagre-recruit
- University of Wisconsin, Madison
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Nagre-recruitPhase 1
- University of Wisconsin - Carbone Cancer Center, Madison
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Nagre-recruitPhase 3
- University of Wisconsin Carbone Cancer Center- University Hospital, Madison
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Nagre-recruitPhase 1/2
- University of Wisconsin-Madison Carbone Cancer Center, Madison
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Nagre-recruitPhase 2
- University of Wisconsin, Madison
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Nagre-recruitPhase 3
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Study of 18F-FFNP Breast PET/MRI
Nagre-recruitPhase 2
- UW Carbone Cancer Center, Madison
Biomarkers to Detect Endocrine Therapy Resistance
Nagre-recruitPhase 2
- UW Carbone Cancer Center, Madison
Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer
Nagre-recruitPhase 2
- University of Wisconsin Carbone Cancer Center, Madison
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Nagre-recruitPhase 3
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Nagre-recruitObservasyonal na pag-aaral
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Nagre-recruitPhase 4
- University of Wisconsin, Madison
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Nagre-recruitPhase 1
- UW Carbone Cancer Center, Madison
Pag-aaral para sa Kanser sa Suso sa ibang lungsod
- New York City, NY136 pag-aaral
- Houston, TX126 pag-aaral
- Boston, MA112 pag-aaral
- Nashville, TN81 pag-aaral
- Los Angeles, CA73 pag-aaral
- Edison, NJ68 pag-aaral
- St. Louis, MO64 pag-aaral
- Queens, NY64 pag-aaral
- Durham, NC64 pag-aaral
- Chicago, IL59 pag-aaral
- Philadelphia, PA56 pag-aaral
- Dallas, TX55 pag-aaral
Iba pang pag-aaral sa Madison
- Kanser sa Prostate29 pag-aaral
- Colorectal Cancer23 pag-aaral
- Metastatic Cancer21 pag-aaral
- Acute Myeloid Leukemia16 pag-aaral
- Non-Small Cell Lung Cancer16 pag-aaral
- Melanoma15 pag-aaral
- Kanser (lahat ng uri)14 pag-aaral
- Kanser sa Ovary13 pag-aaral
- Kanser sa Tiyan11 pag-aaral
- Kanser sa Pancreas10 pag-aaral
- Kanser sa Baga10 pag-aaral
- Multiple Myeloma9 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.